Clinical Trial Update: Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib plus gemcitabine in relapsed mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Lymphoma | Phase 2 | Status: COMPLETED